hce (Q81083)

From MaRDI portal

!

This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use the normal view instead:

hce

Design and Analysis of Hierarchical Composite Endpoints
Language Label Description Also known as
default for all languages
No label defined
    English
    hce
    Design and Analysis of Hierarchical Composite Endpoints

      Statements

      0 references
      0.5.0
      16 January 2023
      0 references
      0.0.2
      26 September 2022
      0 references
      0.0.8
      16 November 2022
      0 references
      0.4.0
      5 January 2023
      0 references
      0.5.8
      17 August 2023
      0 references
      0.5.9
      31 October 2023
      0 references
      PACKAGES.rds
      9 July 2026
      0 references
      0.6.0
      12 March 2024
      0 references
      0.6.3
      19 August 2024
      0 references
      0.6.5
      16 October 2024
      0 references
      0.6.7
      7 January 2025
      0 references
      0.7.0
      5 March 2025
      0 references
      0.7.2
      14 May 2025
      0 references
      0.8.0
      11 July 2025
      0 references
      0.8.5
      22 August 2025
      0 references
      0.8.8
      5 December 2025
      0 references
      0.9.0
      29 January 2026
      0 references
      0.9.1
      12 March 2026
      0 references
      0.9.3
      13 May 2026
      0 references
      0.9.4
      26 June 2026
      0 references
      0 references
      0 references
      0 references
      26 June 2026
      0 references
      Simulate and analyze hierarchical composite endpoints with univariate distributions by Gasparyan, Koch, Brunner in (2025) in “The Univariate Distribution of Hierarchical Composite Endpoints and the Condorcet Non-transitivity Paradox.” (Biometrical Journal 68 (3), <doi:10.1002/bimj.70140>). Includes implementation for the kidney hierarchical composite endpoint as defined in Heerspink HL et al (2023) “Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression” (Journal of the American Society of Nephrology 34 (2): 2025–2038, <doi:10.1681/ASN.0000000000000243>). Win odds, also called Wilcoxon-Mann-Whitney or success odds, is the main analysis method, but other win statistics (win probability, win ratio, net benefit) are also implemented in the univariate case. The win probability analysis is based on the Brunner-Munzel test and uses the DeLong-DeLong-Clarke-Pearson variance estimator, as described by Brunner and Konietschke (2025) in “An unbiased rank-based estimator of the Mann–Whitney variance including the case of ties” (Statistical Papers 66 (1): 20, <doi:10.1007/s00362-024-01635-0>). Includes implementation of a new Wilson-type, compatible confidence interval for the win odds, as proposed by Schüürhuis, Konietschke, Brunner (2025) in “A new approach to the nonparametric Behrens–Fisher problem with compatible confidence intervals.” (Biometrical Journal 67 (6), <doi:10.1002/bimj.70096>). Stratification and covariate adjustment are performed based on the methodology presented by Koch GG et al. in “Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them” (Statistics in Medicine 17 (15-16): 1863–92). For a review, see Gasparyan SB et al (2021) “Adjusted win ratio with stratification: Calculation methods and interpretation” (Statistical Methods in Medical Research 30 (2): 580–611, <doi:10.1177/0962280220942558>).
      0 references

      Identifiers

      0 references